11 January 2022

Nivolumab (Opdivo) for Oesophageal Cancer

Nivolumab is a drug which blocks a protein, called the programmed death-1 (PD-1) receptor, on thesurface of certain immune cells (called T-cells). By blocking the PD-1 receptor this triggers the T-cellsto find and kill cancer cells. Nivolumab is given as a drip directly into a vein in the hand or arm. Studiesof nivolumab in this population are currently being conducted to determine if it may extend survivalor slow the progression of the disease.

Download PDF

Get in touch

Register your details and one of our team will be in touch shortly.

Contact